Weight-loss drug makers announce pricing agreement with Trump | Health News
United States President Donald Trump, Eli Lilly and Novo Nordisk have unveiled a deal to slash the prices of popular GLP-1 weight‑loss drugs for the government’s Medicare and Medicaid programme, as well as for cash payers.The deal, announced on Thursday, is aimed at increasing access to treatments through US Medicare for people aged 65 and above and the Medicaid programme for low-income people, which together provide healthcare coverage for nearly half of all Americans.Recommended Stories list of 4…
